drugset / Trial / NCT00193973
Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma
Phase 2
Completed
20 enrolled
Trans Tasman Radiation Oncology Group
Australasian Leukaemia and Lymphoma Group · collab
NaSingle-groupOpen-labelTreatment
Summary
Idarubicin combined with high dose methotrexate and moderate dose radiotherapy will achieve similar survival outcomes but with reduced neurotoxicity compared to regimens using methotrexate with high dose radiotherapy.
Timeline
- Start
- 2001-07
- Primary completion
- 2008-07
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cytarabine | Small molecule | — | Intrathecal |
| Comparator | Idarubicin | Small molecule | 15 mg/m2 | — |
| Comparator | Methotrexate | Small molecule | 1 g | — |
| Comparator | filgrastim | Protein / enzyme biologic | 5 ug/kg | — |